The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation
Currently, the predominant approach to accessioning donor cells for hematopoietic cell transplantation (HCT) is the use of granulocyte colony-stimulating factor (G-CSF) treatment of the donor for a number of days, followed by leukapheresis of peripheral blood progenitor cells (G-PBs) [1]. Over 70% of adult allogeneic HCT procedures utilize G-PBs in the United States and Canada [2]. Studies have shown that allogeneic transplantation with unstimulated bone marrow (BM) allograft results in lower rates of acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) and improved quality of life compared with G-PB grafts [1 –3].
Source: Experimental Hematology - Category: Hematology Authors: Stephen Couban, Peggy C. Wong, Kirk R. Schultz Source Type: research
More News: Bone Graft | Canada Health | Filgrastim | Hematology | Neulasta | Neupogen | Study | Transplants | USA Health